UNITED KINGDOM — Insulet Corp. has announced the commercial launch of its Omnipod 5 Automated Insulin Delivery (AID) System in the United Kingdom.
This tubeless AID system, which was previously introduced in the United States last year, has revolutionized diabetes management by simplifying the process.
The expansion of Omnipod 5 into the UK signifies Insulet’s commitment to providing broader access to this innovative system on a global scale.
The Omnipod 5 System is the first CE-marked tubeless hybrid closed-loop system that seamlessly integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System.
By automatically adjusting insulin delivery and safeguarding against high and low glucose levels, this system enhances diabetes management.
It comprises the tubeless pod equipped with SmartAdjust technology and the Omnipod 5 Controller, which features an integrated SmartBolus Calculator. The system is interoperable with the Dexcom G6 CGM, enabling AID functionality.
Utilizing SmartAdjust technology, the Omnipod 5 System constantly receives CGM values and trends every five minutes, enabling it to predict glucose levels for the next hour.
Based on the user’s individualized glucose target, the system adjusts insulin delivery by increasing, decreasing, or pausing it.
The Omnipod 5 System’s advanced technology combined with its user-friendly design has significantly reduced the burden of diabetes management and improved the quality of life for individuals living with the condition.
With the National Institute of Health and Care Excellence (NICE) expected to approve the hybrid closed-loop system in England and Wales later this year, the availability of Omnipod 5 will provide evidence-based treatment options for individuals with type 1 diabetes in the United Kingdom.
Insulet has collaborated with the National Health Service (NHS) to ensure smooth access to Omnipod 5 at all levels, facilitating its integration into the healthcare system.
According to a research report, the global insulin delivery devices market was valued at US$12.5 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 7.4% by 2030.
This underscores the vast market potential for innovative solutions like the Omnipod 5 System.
In recent developments, Insulet announced the FDA clearance of Omnipod GO, an insulin delivery device specifically designed for people with type 2 diabetes who typically require daily injections of long-acting insulin.
The commercial launch of Omnipod GO in the United States is anticipated in 2024.
Furthermore, Insulet acquired the assets of Automated Glucose Control LLC, a California-based company focused on developing and commercializing state-of-the-art AID technology.
The transaction, valued at US$25 million, includes licensing rights from the University of California and other intellectual properties, further bolstering Insulet’s commitment to advancing AID technology.
In terms of stock performance, Insulet shares (PODD) have experienced a decline of 3.1% in the past six months, contrasting with the industry’s overall rise of 7%.
Expanding its global reach, Insulet Corp. has announced its plans to launch the Omnipod 5 Automated Insulin Delivery (AID) System in Germany later this year.
With its continuous efforts to introduce innovative insulin delivery solutions and gain regulatory approvals, Insulet Corp. is solidifying its position as a leader in the field of diabetes management.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
